Epitalon
A short peptide associated with longevity and telomere-oriented anti-aging discussion in the research market.
Also referenced as: Epithalon
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Epithalon
No FDA label signal · 0 trials · 119 PubMed results
Current evidence for Epitalon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Epitalon has no clinical trials that name it and 119 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What epitalon is
Epitalon is a short synthetic peptide that appears frequently in longevity and anti-aging discussions, especially in communities focused on speculative cellular-aging interventions.
Why it matters
This category draws heavy interest but often has weak labeling discipline. Epitalon is useful as a profile because it lets us represent the anti-aging bucket without pretending that the category has the same regulatory footing as approved metabolic drugs.
Regulatory context
Epitalon is not an FDA-approved anti-aging medicine in the United States. It belongs firmly in the research-market conversation.
Practical reading note
The phrase “anti-aging peptide” is usually more marketing category than medical category. Profiles like this should be read with extra skepticism around mechanism-to-outcome claims.